Elizabeth Brem • UCI Profiles (original) (raw)
- Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2026 Feb 02. Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Ba Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Ayyappan S, Sigmund A, Bond D, Fitzgerald L, Wagner C, Hu B, Stephens DM, Shah H. PMID: 41763973.
View in: PubMed Mentions: Fields:
Translation:Humans - Recurrent plasma cell myeloma with intracytoplasmic Auer rod-like inclusions after autologous hematopoietic stem cell transplantation. Int J Clin Exp Pathol. 2025; 18(9):503-508. Niu C, Brem E, Zhang Y, Ren D, Tran T, Gamayo A, Zhao X, Rezk SA. PMID: 41112523; PMCID: PMC12531499.
View in: PubMed Mentions: Fields: - Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma. Leuk Lymphoma. 2025 Dec; 66(13):2548-2552. Chumnumsiriwath P, Vittayawacharin P, Pinter-Brown L, Brem EA, Griffin SP, Kongtim P, Ciurea SO. PMID: 40840891; PMCID: PMC12767447.
View in: PubMed Mentions: Fields: - R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Dec; 25(12):e1014-e1021. Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Brem EA, Van Etten RA, Nelson EL, Coombs CC, Chan A. PMID: 40681431.
View in: PubMed Mentions: Fields:
Translation:Humans - Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis. Eur J Haematol. 2025 Jun; 114(6):1032-1040. Vittayawacharin P, Lee BJ, E'leimat G, Cao Y, Reid J, Gamayo A, Rezk S, Brem EA, Lee LX, Kongtim P, Ciurea SO. PMID: 40088122; PMCID: PMC12571457.
View in: PubMed Mentions: Fields:
Translation:Humans - Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis. Blood Neoplasia. 2025 Aug; 2(3):100067. Rosenberg AS, Maverakis E, Costello C, Brem EA, Wieduwilt MJ, Luxardi G, Kaesberg P, Abedi K, Herbert S, Tuscano J. PMID: 40948663; PMCID: PMC12432457.
View in: PubMed Mentions: Translation:CTClinical Trials - Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. Cancer Med. 2024 Oct; 13(19):e70310. Lee BJ, Liu J, Griffin SP, Doh J, Ciurea SO, Kongtim P, Brem EA. PMID: 39394843; PMCID: PMC11470199.
View in: PubMed Mentions: Fields:
Translation:Humans - CNS prophylaxis is (mostly) futile in DLBCL. BJC Rep. 2024 Oct 01; 2(1):74. Shieh K, Brem E. PMID: 39516683; PMCID: PMC11523957.
View in: PubMed Mentions: 1 - A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024 Dec; 1(4):100036. Brem EA, Shieh K, Juarez D, Buono R, Jeyakumar D, O'Brien S, Taylor TH, Fruman DA. PMID: 40552135; PMCID: PMC12182841.
View in: PubMed Mentions: 4 - Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities. Semin Hematol. 2023 11; 60(5):285-290. Brem EA, Sehn LH. PMID: 38368147.
View in: PubMed Mentions: 3 Fields:
Translation:Humans - Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023 11 01; 108(11):3025-3032. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. PMID: 37102592; PMCID: PMC10620571.
View in: PubMed Mentions: 7 Fields:
Translation:Humans - Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350. Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. PMID: 37530631; PMCID: PMC10587711.
View in: PubMed Mentions: 20 Fields:
Translation:HumansCellsCTClinical Trials - Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2023 Sep; 111(3):477-484. Lee BJ, Cao Y, Vittayawacharin P, É'Leima G, Rezk S, Reid J, Brem EA, Ciurea SO, Kongtim P. PMID: 37385631.
View in: PubMed Mentions: 9 Fields:
Translation:Humans - Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):749-756. Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. PMID: 37336714.
View in: PubMed Mentions: Fields:
Translation:Humans - Sinonasal lymphoma: A primer for otolaryngologists. Laryngoscope Investig Otolaryngol. 2022 Dec; 7(6):1712-1724. Bitner BF, Htun NN, Wang BY, Brem EA, Kuan EC. PMID: 36544932; PMCID: PMC9764779.
View in: PubMed Mentions: 8 - R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
View in: PubMed Mentions: 5 Fields:
Translation:Humans - Eponyms in Malignant Hematology. Cancer Treat Res Commun. 2022; 32:100594. Brazel D, Kumar P, Benjamin DJ, Brem E. PMID: 35835706.
View in: PubMed Mentions: Fields:
Translation:Humans - Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis. Blood Adv. 2022 02 22; 6(4):1361-1364. Brem EA, O'Brien S. PMID: 34965291; PMCID: PMC8864648.
View in: PubMed Mentions: 4 Fields:
Translation:Humans - Eponyms in medical oncology. Cancer Treat Res Commun. 2022; 31:100516. Kumar P, Brazel D, Benjamin DJ, Brem E. PMID: 35065322.
View in: PubMed Mentions: 2 Fields:
Translation:Humans - SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 03; 13(2):258-264. Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. PMID: 34686472; PMCID: PMC9879719.
View in: PubMed Mentions: 10 Fields:
Translation:HumansCTClinical Trials - Frontline Management of CLL in 2021. JCO Oncol Pract. 2022 02; 18(2):109-113. Brem EA, O'Brien S. PMID: 34288757.
View in: PubMed Mentions: 5 Fields:
Translation:Humans - Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma. Laryngoscope. 2021 11; 131(11):E2727-E2735. Lehrich BM, Abiri A, Goshtasbi K, Birkenbeuel J, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. PMID: 33899946; PMCID: PMC8502199.
View in: PubMed Mentions: 5 Fields:
Translation:Humans - Hemophagocytic Lymphohistiocytosis in the Emergency Department: Recognizing and Evaluating a Hidden Threat. J Emerg Med. 2021 06; 60(6):743-751. Morrissette K, Bridwell R, Lentz S, Brem E, Gutierrez KO, Singh M, Koyfman A, Long B. PMID: 33745765; PMCID: PMC7972988.
View in: PubMed Mentions: 7 Fields:
Translation:Humans - Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2021 03; 62(3):727-730. Lehrich BM, Goshtasbi K, Abiri A, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. PMID: 33054461.
View in: PubMed Mentions: 2 Fields:
Translation:HumansCells - Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly. Curr Hematol Malig Rep. 2019 08; 14(4):228-238. Khan Y, Brem EA. PMID: 31228094.
View in: PubMed Mentions: 8 Fields:
Translation:Humans - Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 02 07; 133(6):566-575. Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM. PMID: 30498064; PMCID: PMC6367646.
View in: PubMed Mentions: 36 Fields:
Translation:HumansAnimalsCells - Hemophagocytic lymphohistiocytosis in the setting of HELLP Syndrome. Clin Case Rep. 2018 Dec; 6(12):2466-2470. Sarkissian S, Khan Y, Farrell D, Constable D, Brem E. PMID: 30564350; PMCID: PMC6293182.
View in: PubMed Mentions: 5 - The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. J Emerg Med. 2017 Aug; 53(2):202-211. Robertson JJ, Brem E, Koyfman A. PMID: 28408234.
View in: PubMed Mentions: 4 Fields:
Translation:Humans - BOK: Oddball of the BCL-2 Family. Trends Cell Biol. 2016 06; 26(6):389-390. Brem EA, Letai A. PMID: 27156889.
View in: PubMed Mentions: 6 Fields:
Translation:HumansAnimalsCells - Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014 Dec; 55(12):2675-7. Brem EA, Davids MS. PMID: 24794805.
View in: PubMed Mentions: Fields:
Translation:Humans - Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. J Emerg Med. 2013 Jul; 45(1):143-9. Brem E, Koyfman A, Foran M. PMID: 23375217.
View in: PubMed Mentions: 4 Fields:
Translation:HumansPHPublic Health - Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol. 2011 Jun; 153(5):599-611. Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, Hernandez-Ilizaliturri FJ. PMID: 21492126; PMCID: PMC3092002.
View in: PubMed Mentions: 33 Fields:
Translation:HumansCells
This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
Start with: newest oldestInclude: line numbers double spacing all authors publication IDs